In Brief: Supreme Court preemption cases
Supreme Court preemption cases: High Court remands to Illinois state court in Chicago the case of Kernatz v. SIMS by electing not to review a writ of certiorari submitted on behalf of SIMS. SIMS argued in the case that liability claims against a device approved under the agency's premarket approval and investigational device exemption processes are preempted by FDA requirements ("The Gray Sheet" Dec. 15, p. 7). The court concurrently elected not to review a petition in the case of Collagen v. Fiore, which also deals with the preemption issue. The two decisions represent the most recent denials by the high court of writs related to the preemption issue following the court's June 26, 1996 ruling in Medtronic v. Lohr. In April 1997, the court chose not to review the case of Ruth Hunter v. Iolab, which focuses on the preemption of state tort claims by FDA's IDE regulations ("The Gray Sheet" April 28, 1997, p. 10). The court also declined to review the case of Collagen v. Mitchell...
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.
FDA Commissioner Marty Makary stated in a new interview that there will be no significant reorganization of the agency, despite earlier reports. Using his “guiding principles” of common sense and gold-standard science, he plans to focus on reforms including improved pathways for medical AI and food safety as well as addressing employee morale.
While Roche continues to view China as a strategic growth market, a sharp 23% decline in Chinese diagnostics sales offset gains in other regions and segments. Despite near-term headwinds, Roche is betting on strong instrument placement growth across its Core Lab, Molecular, and Near Patient Care segments to fuel future demand for consumables and services–key components of its long-term medtech strategy.